First Refractory Gastric Cancer Patient Dosed in Phase II Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

MiNK Therapeutics announced the first patient dosed in a Phase II investigator sponsored study for agenT-797 in second line gastroesophageal cancer, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center.